PT  - JOURNAL ARTICLE
AU  - Marsh, Kathleen
AU  - Allickson, Kayla
AU  - Jesz, Amanda
AU  - Hanson, Cheryl
AU  - Newman, Donna
AU  - Martin-Macintosh, Erica
TI  - Logistics of Adopting <sup>177</sup>Lu-Vipivotide Tetraxetan Therapy in a Community-Based Hospital Setting
AID  - 10.2967/jnmt.124.268039
DP  - 2025 Mar 01
TA  - Journal of Nuclear Medicine Technology
PG  - 68--71
VI  - 53
IP  - 1
4099  - http://tech.snmjournals.org/content/53/1/68.short
4100  - http://tech.snmjournals.org/content/53/1/68.full
SO  - J. Nucl. Med. Technol.2025 Mar 01; 53
AB  - Prostate cancer is a leading cause of cancer death in men. Advanced disease may progress to metastatic castration-resistant prostate cancer. In March 2022, 177Lu-vipivotide tetraxetan was U.S. Food and Drug Administration–approved for patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have previously received other therapies, including androgen deprivation and taxane therapies. Methods: Although preliminary data for 177Lu-vipivotide tetraxetan has shown extension of overall survival of patients, there is little literature about realistically initiating 177Lu-vipivotide tetraxetan into non–academic-based clinical practices. Results: This article presents a multidisciplinary practice implementation workflow for 177Lu-vipivotide tetraxetan. It also highlights the challenges and considerations for initiating such a theranostics practice. Conclusion: The aim of this work is to help nontertiary medical centers improve patient accessibility for beneficial radiopharmaceutical therapies, specifically 177Lu-vipivotide tetraxetan.